Veracyte (VCYT)
(Delayed Data from NSDQ)
$36.48 USD
-0.86 (-2.30%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $36.60 +0.12 (0.33%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
VCYT 36.48 -0.86(-2.30%)
Will VCYT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for VCYT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VCYT
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
VCYT: What are Zacks experts saying now?
Zacks Private Portfolio Services
HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket
ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket
Hologic (HOLX) Q4 Earnings Miss Estimates
Other News for VCYT
Wellington Management Group LLP's Strategic Reduction in Veracyte Inc Holdings
Veracyte price target raised to $44 from $40 at Scotiabank
Veracyte price target raised by $4 at Scotiabank, here's why
Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), Ligand Pharma (LGND)
Scotiabank Reaffirms Their Buy Rating on Veracyte (VCYT)